Sac-TMT, also known as SKB264 or MK-2870, represents the first asset in Kelun’s multitarget, multibillion-dollar ADC ...

After six straight quarters in which Eli Lilly or Novo Nordisk achieved the highest year-over-year revenue growth among the ...

Incyte’s previously disclosed phase 3 win in relapsed or refract | In the phase 3 inMIND study, Monjuvi—added to Bristol ...

With Robert F. Kennedy Jr. slated to take the top spot at the U.S. | RFK Jr. has previously expressed a desire to put a stop ...

Eight months after snaring an inaugural FDA green light, Merck & Co. is bolstering the case for the chief asset in its $11.5 ...

On a routine basis in recent years, headlines about layoffs in the biopharma industry have surfaced as companies large and ...

While President-elect Donald Trump has already made his leadership picks for the Department of Health and Human Services (HHS ...

Two months after Sanofi completed construction in France of its innovative Modulus vaccine and biologics plant—which can be ...

More than three years into a lawsuit accusing competitor Natera of disparaging its cancer blood test, Guardant Health has ...

President-elect Donald Trump has put forward a formal pick for the top spot at the U.S. Food and Drug Administration. | ...

Before Exelexis’ Cabometyx can pass muster with the FDA in its hopeful neuroendocrine tumors indication next April, it will have to first face the agency’s Oncologic Drugs Advisory Committee ( | The ...

In a contrarian take offered by BMO Capital Markets' Evan Seigerman, the analyst said Robert F. Kennedy Jr. may not rock the ...